Adlai Nortye at Morgan Stanley global healthcare conference: RAS push

Adlai Nortye highlighted early encouraging clinical signals for AN9025, its oral pan-RAS(ON) inhibitor, and reported $232 million of cash as of June 30, 2025, providing operational runway through 2028. AN9025 showed roughly 250x greater preclinical potency than divarasib, while AN4035, a CEACAM5-targeted ADC carrying a RAS-inhibitor payload, dosed its first Phase I patient. The central valuation catalyst remains human data: full AN9025 once-daily Phase Ia results are expected in 1H 2027 and full AN4035 Phase Ia data in 2H 2027; management cautioned that preclinical differentiation must be validated clinically.

Analysis

ANL’s investable value remains almost entirely an option on clinical translation, not on the stated preclinical potency differential. The relevant benchmark is not whether AN9025 produces isolated responses, but whether it can demonstrate a usable exposure-response relationship and combination tolerability at doses competitive with RMC-6236 and ERAS-801/other emerging RAS-pathway approaches. The absence of disclosed patient counts, confirmed response durability, RP2D, or a defined biomarker-selected population means the expansion-cohort decision is directionally encouraging but not yet a valuation-grade de-risking event.

The nearer-term risk is financing and execution rather than an immediate fundamental catalyst. A nominal runway through 2028 assumes a development plan that could expand materially if front-line chemotherapy combinations progress; biotech markets typically capitalize anticipated spend well before cash exhaustion, especially after an initial efficacy signal raises the cost of pursuing multiple cohorts. The dated cash disclosure also needs reconciliation to current cash, quarterly burn, ADS count, warrant overhang, and China-partner economics before assigning any enterprise-value floor.

Competitive dynamics favor RVMD in the next 6-12 months because it has the more established clinical-data reference set and can benefit if ANL’s claimed differentiation fails to reproduce in humans. Conversely, credible ANL data showing durable activity with materially lower GI/skin toxicity would pressure the premium assigned to RAS-platform incumbents, but that is a 2027 event; the ADC is an even longer-duration call option because target expression, payload release, and combination safety each add independent failure modes. Consensus may underappreciate that an ADC bearing a targeted payload can still face narrow therapeutic index constraints, while over-crediting the platform before the first program establishes tumor-selective delivery.

No standalone ANL long is warranted ahead of interpretable human data unless its enterprise value falls near net cash after adjusting for expected 12-month burn. The key falsifiers are a safety-related dose ceiling, inability to sustain dose intensity in chemotherapy combinations, response rates/duration below contemporary pan-RAS datasets, or a capital raise before a substantive data package.

Key Decisions for Investors

• Maintain no directional ANL position over the next 1-3 months; treat the name as an event-driven watchlist candidate, not a conference-driven rerating. Reassess only after disclosure of enrolled patients, dose levels, objective responses, duration, and discontinuation rates.
• For 6-12 month RAS exposure, favor long RVMD versus short ANL only if ANL has sufficient borrow and liquidity; size as a small catalyst hedge rather than a core pair. The trade expresses RVMD’s clinical lead against ANL’s unvalidated claims, with cover/stop discipline if ANL releases independently verified durable response and tolerability data before RVMD’s next material update.
• Set an ANL financing alert: a raise before a full data package, or quarterly operating burn materially above the implied runway, is a negative catalyst and supports avoiding or shorting rallies if borrow is available. Conversely, defer any short if enterprise value approaches adjusted net cash, where downside becomes balance-sheet constrained.
• Monitor RVMD and ERAS clinical disclosures as read-throughs rather than direct substitutes. Better-than-expected class-wide combination safety would expand the addressable market and improve ANL’s eventual probability-weighted value; class-wide toxicity or weak durability would invalidate the broad pan-RAS thesis and favor reducing exposure across the group.
• Do not use ANL options without verified open interest and bid-ask spreads; the 2027 catalyst horizon makes illiquid short-dated calls structurally unattractive. If liquid LEAPS become available after a valuation reset, a small defined-risk call position is preferable to equity because the upside case is highly binary.